Showing results (1-10 of 286) with videos related to
Sort By:
Pageof 29
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 14, 2025
Background HIV Incidence in PURPOSE 1 and 2 PrEP trialsJean-Jacques ParientiExpert Opinion on Pharmacotherapy|May 31, 2002
Cytokine therapy or structured treatment interruptions in HIV infection: which is best?Jean-Jacques ParientiContemporary Clinical Trials|November 18, 2006
Cluster-crossover design: a method for limiting clusters level effect in community-intervention studiesJean-Jacques Parienti, Oliver KussExpert Opinion on Drug Metabolism & Toxicology|March 23, 2011
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulationJean-Jacques Parienti, Gilles PeytavinPlos One|November 16, 2012
Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted studyLaurent Hocqueloux, Philippe Choisy, Gwenaël Le Moal, et al.BMC Medical Research Methodology|September 22, 2006
Methodological standards in non-inferiority AIDS trials: moving from adherence to complianceJean-Jacques Parienti, Renaud Verdon, Véronique MassariClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 15, 2026
Selected Industry Highlights From IDWeek 2025Jean-Jacques Parienti, Shangxin Shaun Yang, Steven GrinspoonPlos One|March 17, 2016
The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-AnalysisPierre Branger, Jean-Jacques Parienti, Maria Pia Sormani, et al.The Journal of Infectious Diseases|February 20, 2019
Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine CandidateJean-Daniel Lelièvre, Laurent HocquelouxVirologie (Montrouge, France)|August 16, 2019
[Clinical and therapeutic implications of quantifying HIV reservoirs]Laurent Hocqueloux, Jean-Paul ViardPageof 29